Funding for this research was provided by:
the CSCO-Qilu cancer research fund project (Y-Q201801-066)
the Science and Technology Research Program of Chongqing Municipal Education Commission (KJQN201900106)
Article History
Received: 16 December 2020
Accepted: 17 May 2021
First Online: 2 June 2021
Declarations
:
: The study was approved by the Clinical Research Management Committee of Chongqing Cancer Hospital (No. 2019-linshen-027). The study received informed consent signed by all patients.
: The study received written informed consent for publication by all patients.
: This study was supported by the Qilu pharmaceutical Co. Ltd.